model [18] , no data are available about the most efficient growth factor concentrations in vivo. The [19, 20] (Fig. 1A  and B) . In group B, the chambers were implanted in an upside-down fashion on the back of the rats with the opening of the chamber facing the dorsal muscle and with fixation of the chambers (Fig. 1C and D) . In both groups, the matrices consisted of 500 l fibrin gel with identical fibrinogen and thrombin concentrations (10 
aim of this study was to evaluate a suitable subcutaneous implantation technique in rats as an in vivo screening tool and to quantitatively evaluate the angiogenetic effects of VEGF and bFGF immobilized in a fibrin-based drug delivery system in the subcutaneous rat model.

Materials and methods
Experimental design
In phase 1, a suitable subcutaneous implantation technique was evaluated. For this purpose, six male Lewis rats were divided into two identical groups (A and B). In animals from group A, two teflon isolation chambers containing fibrin gel matrices were implanted subcutaneously in conventional implantation technique with the opening of the chamber facing the dorsal skin of the rat and without any fixation of the chambers
mg/ml fibrinogen, 2 I.U./ml thrombin). The explantation interval was 10 days after the initial operation for all groups (including 6 matrices per group and time-point).
In phase 2, the angiogenetic effects of VEGF and bFGF immobilized in a fibrin-based drug delivery system were quantitatively assessed in the subcutaneous rat model (Fig. 2 
). Four teflon isolation chambers containing fibrin gel matrices were implanted subcutaneously in an upside-down fashion on the back of 30 Lewis rats. The matrices consisted of 500 l fibrin gel with two different fibrinogen concentrations (10 mg/ml or 40 mg/ml fibrinogen, 2 I.U./ml thrombin), loaded with VEGF165 and bFGF in five different concentrations (0 to 250 ng/ml each). The explantation intervals were 3, 7 and 14 days after the initial operation for all groups (including 4 matrices per group and time-point).
Isolation chamber and composition of the fibrin matrix 
Immunohistology Lectin
Rat endothelial cells were detected immuno-histochemically using the lectin Bandeiraea Simplicifolia agglutinin (BS-1) as described previously [21] . Paraffinated (Fig. 7) . Except for blood vessels there was no significant staining by ASMA in the fibrovascular tissue.
Fig. 5 H&E stainings of matrices of phase one explanted after 10 days. Matrices of group A, which were implanted in a conventional manner, showed an inhomogeneous clot structure (A). Note the small area of contact between the clot and the adjacent fibrovascular tissue (B). In comparison, matrices implanted using the upside-down implantation technique displayed high adhesion of the fibrin clot to the subjacent tissue and a more homogeneous structure (CϩD).
AϩC ϭ magnification ϫ25; B ϩD ϭ magnification ϫ100. F ϭ Fibrin gel; G ϭ Granulation tissue; *ϭ Interface. (Fig. 8) . (Fig. 9) . (Fig. 10) .
Fig. 6 H&E stained cross sections of matrices explanted 1 week after the initial operation using no growth factors (A), 25 ng/ml VEGF and bFGF (B) and 250 ng/ml VEGF and bFGF (C). By the use of 250 ng/ml VEGF and bFGF there was a significant contraction of the fibrin gel matrix after 1 week. The use of growth factors increased height of fibrovascular tissue at the matrix-host interface. Magnification ϫ25.
Morphometric analysis
In phase two, morphometric analysis of the constructs demonstrated a significant decrease of construct height following appli-
In all groups, the matrix height did not significantly differ 3 days after implantation. At day 14, all fibrin clots were almost completely degraded in all groups. The use of growth factors with a concentration of 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF significantly increased height
Fig. 7 Representative micrographs of fibrovacular tissue adjacent to matrices explanted after one week without growth factors (A, D, G, J), with 25 ng/ml VEGF and bFGF (B, E, H, K) and with 100 ng/ml VEGF (C, F, I, L). (A, B, C) H&E stained cross sections; (D, E, F) ED1 staining of macrophages; (G, H, I) Lectin staining of endothelial cells; (J, K, L) Alpha-smooth muscle actin staining of blood vessels. Presence of macrophages was independent of added growth factors (D, E, F). Number of blood vessels increased when growth factors were used (G-L
The total number of blood vessels counted in the fibrovascular tissue adjacent to the matrices of lectin stained cross-sections was significantly increased when using of 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF in comparison to growth factor-free fibrin clots at 1 week (185 Ϯ 45 vessels per field of view [FOV] and 168 Ϯ 38 vessels per FOV versus 110 Ϯ 21 vessels per FOV) and at 2 weeks (179 Ϯ 64 vessels per FOV and 168 Ϯ 42 vessels per FOV versus 99 Ϯ 28 vessels per FOV). There was no further increase of blood vessel numbers when higher concentrations of growth factors were used
Similar results could be obtained regarding average fraction of blood vessels and total area of blood vessels (data not shown). There was no difference regarding average blood vessel size and standard deviation of blood vessel size between the different growth factor concentrations (data not shown).
Discussion
In phase one of this study, a technique for suitable subcutaneous implantation was evaluated. In the literature, mainly two implantation techniques are described for subcutaneous implantation into the dorsal space of small animals: first, the implantation without any chamber, using fibrin glue alone [22] or in combination with other matrices for example with decalcified spongiosa blocks to study tissue ingrowth into fibrin [23] , and second, the subcutaneous implantation without any fixation of the chamber and with the opening of the chamber facing the dorsal skin of the rat, which is referred to as the conventional technique in our study [19, 20] . In comparison to these techniques, the upsidedown implantation provides a fixation of the chamber to the subjacent tissue and the opening of the chamber faces the dorsal muscle of the rat.
Here we demonstrated that constructs implanted in the upsidedown manner show a much better adhesion at the matrix-host interface and a much more homogeneous clot structure than constructs implanted using the conventional implantation technique. This could be explained by the reduced shear forces due to fixation of the chamber and by implantation of the construct in an upsidedown fashion whereby a continuous contact of the fibrin gel to the host is provided. Another subcutaneous implantation model, which is described in the literature, uses chambers with a 10 hole-perforated bottom slip [24] . These chambers are not suitable for our study because our chamber should provide a high surface area for growth factor interactions with the subjacent tissue.
In phase two of this study, we demonstrate that VEGF and bFGF immobilized in a fibrin-based drug delivery system efficiently modulate angiogenesis in the subcutaneous model in the rat.
Fig. 8 Morphometric analysis of construct height (fibrinogen diluted). There is a significant decrease of construct size and volume following application of 100 and 250 ng/ml VEGF and bFGF in comparison to 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF alone at 1 week. In all groups, the matrix volume and size did not significantly differ 3 days after implantation. At day 14, all fibrin gels were almost completely degradated in all groups. *P < 0.05 versus 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF;
# P < 0.05 versus 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF. A known feature of the fibrin matrix is fibrinolysis and degradation over time [25] , a phenomenon also observed in this study. To control the degradation of fibrin gel matrix, aprotinin was used in this study to slow down fibrinolysis via inhibition of plasmin. Because the degradation of the matrix is directly related to aprotinin concentration, we used the same aprotinin concentration of 1500 K.I.E./ml in all fibrin gel matrices in this study to delay fibrinolysis.
Fig. 9 Morphometric analysis of height of fibrovascular tissue (fibrinogen diluted). The use of growth factors with a concentration of 25 ng/ml VEGF and bFGF and 100 ng/ml VEGF significantly increased height and volume of fibrovascular tissue at the matrix-host interface in comparison to growth factor-free controls at 1 and 2 weeks. Higher concentrations did not further increase tissue formation. *P < 0.05 versus no growth factors (1 week explantation time-point); # P < 0.05 versus no growth factors (2 weeks explantation time-point).
Fig. 10 Morphometric analysis of total number of blood vessels (fibrinogen diluted
Fibrin gel is already established for delivery of growth factors such as VEGF and bFGF [9] . VEGF and bFGF bind specifically and saturably to fibrinogen [15, 17] . We used the 165 iso form of VEGF because of its constant and controlled release within the fibrin clot in contrast to VEGF 121, which binds very weakly with the clot [9] . bFGF interacts strongly with the fibrin clot and is released in a slow manner. It is well known that the greatest angiogenetic effect of VEGF is observed together with bFGF and the combination of VEGF and bFGF shows synergistic activity on angiogenesis [9] . [9] . In addition, thrombin concentration at the time of clotting has the most profound influence on fibrin clot structure, a factor that remains constant for all groups in the study [26] . Because [27] . The fibrin gel can also serve as a cell carrier [21, 28] or as a local gene delivery system [29] . Eventually the implantation into 'smart' growth factor-enhanced matrices will facilitate upscaling of bioartificial devices for larger-volume applications. 
Conclusion
